1. (1) For each patient or human research subject receiving radiopharmaceutical therapy and hospitalized for compliance with Rule 0400-20-07-.35, a licensee shall:

   1. (a) Quarter the patient or the human research subject either in:

      1. 1. A private room with a private sanitary facility; or
      2. 2. A room, with a private sanitary facility, with another individual who also has received radiopharmaceutical therapy and who also cannot be released under Rule 0400-20-07-.35;
   2. (b) Visibly post the patient’s or the human research subject’s room with a “Caution Radioactive Materials” sign;
   3. (c) Note on the door or in the patient’s or human research subject’s chart where and how long visitors may stay in the patient’s or the human research subject’s room; and
   4. (d) Either monitor material and items removed from the patient’s or the human research subject’s room to determine that their radioactivity cannot be distinguished from the natural background radiation level with a radiation detection survey instrument set on its most sensitive scale and with no interposed shielding, or handle the material and items as radioactive waste.
2. (2) The radiation safety officer, or his or her designee, and the authorized user shall be notified immediately if the hospitalized patient or human research subject dies or has a medical emergency.

Authority: T.C.A. §§ 4-5-201, et seq.; 68-202-101, et seq.; and 68-202-201, et seq. Administrative History: Original rule filed February 22, 2012; effective May 22, 2012.